Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Carpipramine in psychoses].

G Garreau, D Sechter

    L'Encephale
    |January 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Carpipramine effectively treats psychomotor deficits in schizophrenia, particularly in hebephrenic and depressed subtypes. Higher doses manage anxiety and delusions in paranoid schizophrenia, showing distinct antidelusional and desinhibitory actions.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Sexual dysfunction and depression: Validity of a French version of the ASEX scale].

    L'Encephale·2013
    Same author

    Room-temperature ferromagnetism of all-epitaxial β-Fe-Ge/diamond-Ge/β-Fe-Ge trilayers.

    Journal of physics. Condensed matter : an Institute of Physics journal·2013
    Same author

    [The severe depression : a clinical and evolutive reality].

    L'Encephale·2010
    Same author

    [Racing mania does not exist any more, manic-depressive psychosis even more so. How about schizophrenia?].

    L'Encephale·2008
    Same author

    [The therapeutic alliance in the initial stages of the management of depression by the general practitioner].

    L'Encephale·2008
    Same author

    Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism.

    Current pharmaceutical design·2007
    Same journal

    Measuring antidepressant side effects in military personnel - Clinical validation of the French version of the UKU-SERS-Pat Scale: A comparative study of patient and clinician ratings.

    L'Encephale·2026
    Same journal

    [Empowerment in addictology].

    L'Encephale·2026
    Same journal

    Evaluation of the links between smoking and conspiracy mentality.

    L'Encephale·2026
    Same journal

    Use of a relevance assessment tool in therapeutic residential care: A real world study.

    L'Encephale·2026
    Same journal

    Prevalence and characteristics of domestic violence in a sample of adult psychiatric outpatients: A cross-sectional study.

    L'Encephale·2026
    Same journal

    From representations to practice: how professionals describe supporting parents with psychiatric or somatic illness or disability.

    L'Encephale·2026
    See all related articles

    Area of Science:

    • Psychiatry
    • Pharmacology

    Background:

    • Carpipramine is an antipsychotic medication.
    • Previous studies have explored its efficacy in various psychotic disorders.

    Purpose of the Study:

    • To evaluate the efficacy of carpipramine in a cohort of 131 psychotic patients.
    • To synthesize existing international research on carpipramine's therapeutic effects.

    Main Methods:

    • A survey of 131 psychotic subjects treated with carpipramine.
    • A comprehensive synthesis of Japanese, German, and French publications on the drug.

    Main Results:

    • Carpipramine demonstrated significant desinhibitory effects on motor retardation, lack of energy, and affective blunting, especially in hebephrenic and depressed schizophrenic patients.

    Related Experiment Videos

  • Low doses worsened paranoid schizophrenic symptoms; higher doses mitigated emergent delusional and anxious phenomena.
  • The drug exhibits both antidelusional and desinhibitory actions.

    • Conclusions:

    • Carpipramine is beneficial for psychomotor deficits in schizophrenia, even those resistant to other antidepressants.
    • It possesses a dual action, addressing both negative symptoms and specific positive symptoms at appropriate dosages.